natgillin/translations-raw huggingface dataset:
Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.) of these clearance pathways may increase or decrease posaconazole plasma concentrations, respectively.
eritromicin, itd.) ali induktorji (npr. rifampicin, rifabutin, določeni antikonvulzivi, itd.) teh poti izločanja povečajo ali zmanjšajo koncentracije posakonazola v plazmi.
Proportion (%) of patients with proven/probable IFIs On-treatment periodb
Vrednost p Odstotek (%) bolnikov z dokazanimi oziroma verjetnimi invazivnimi glivnimi okužbami Obdobjezdravljenjab
Do not switch between taking Posaconazole tablets and posaconazole oral suspension without talking to your doctor or pharmacist because it may result in a lack of efficacy or an increased risk of adverse reactions.
Ne preidite na jemanje tablet posakonazola,čejemljete peroralno suspenzijo posakonazola, in obratno, ne da bi seposvetovali z zdravnikom ali farmacevtom, saj lahko pride do pomanjkanja učinkovitosti alipovečanegatveganjazaneželeneučinke.
In heart transplant patients on stable doses of ciclosporin, posaconazole oral suspension 200 mg once daily increased ciclosporin concentrations requiring dose reductions.
Pri bolnikih s presajenim srcem, ki prejemajo stabilne odmerke ciklosporina,jeperoralnasuspenzijaposakonazola v odmerku 200mg enkrat na dan povečala koncentracijo ciklosporina, tako da jebilopotrebno zmanjšanje njegovega odmerka.
The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole.
Zdravljenje s posakonazolom je trajalo povprečno80 dni in s flukonazolom77 dni.
Therefore, trough concentrations that fall in the upper part of the usual therapeutic range should be targeted and careful attention should be paid to clinical signs and symptoms, laboratory parameters and tissue biopsies.
Zatomorabiticiljna najnižja koncentracija sirolimusa v zgornjem delu običajnega terapevtskega razponain posebno pozornost je treba namenitikliničnimznakomin simptomom,laboratorijskimparametromin tkivnimbiopsijam.
The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels.
Dodatek posakonazola med zdravljenjem z atazanavirjem oziroma zatazanavirjem in ritonavirjem je bilpovezan s povečanjemkoncentracijebilirubina vplazmi.
11 of 24 patients who had proven or probable fusariosis were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 124 days and up to 212 days.
11 od 24 bolnikov, ki so dokazano ali verjetno imeli fuzariozo, so uspešno zdravili s peroralnosuspenzijo posakonazola 800 mg/dan v deljenih odmerkih.Srednjavrednosttrajanjazdravljenjajebila 124 dni, zdravljenjepajelahkotrajalo do 212 dni.
Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below.
Sočasna uporaba posakonazola in substratov CYP3A4lahko zelo poveča izpostavljenost tem substratom, kot kažejo spodajopisaniučinki na takrolimus,sirolimus, atazanavir in midazolam.
Echocardiography revealed no indication of cardiac decompensation in a repeat dose safety pharmacology study in rats at a systemic exposure 1.4-fold greater than that achieved therapeutically.
Vfarmakološki študiji varnosti ponavljajočih se odmerkov ehokardiografija pri podganah nipokazalaznakov srčne dekompenzacije pri sistemski izpostavljenosti, ki je bila 1,4-krat večja od terapevtskodosežene.
Following single-dose administration of posaconazole oral suspension, there was no effect of mild and moderate renal impairment (n=18, Cl cr ≥ 20 mL/min/1.73 m2) on posaconazole pharmacokinetics; therefore, no dose adjustment is required.
Po enkratnemodmerku peroralne suspenzije posakonazolablagain zmernaokvara ledvic (n = 18,očistekkreatinina ≥20 ml/min/1,73 m2)nista vplivali na farmakokinetiko posakonazola, zatoprilagoditevodmerka ni potrebna.
Clinical success rates in Oropharyngeal Candidiasis Endpoint
Klinična uspešnost pri orofaringealni kandidozi
At exposures lower than those obtained at therapeutic doses in humans, posaconazole caused skeletal variations and malformations, dystocia, increased length of gestation, reduced mean litter size and postnatal viability.
Priizpostavljenostih,manjšihod izpostavljenosti, doseženih s terapevtskimiodmerkipričloveku,jeposakonazol povzročil spremembe skeleta in malformacije, distocijo, podaljšanje gestacije, manjšepovprečno število mladičev inmanjšo postnatalno življenjsko sposobnost.
The mean duration of therapy was 29 days for posaconazole and 25 days for fluconazole/itraconazole.
Zdravljenje s posakonazolomjetrajalo povprečno 29 dniin s flukonazolom/itrakonazolom25 dni.
Calcium channel blockers metabolised through CYP3A4 (e.g. diltiazem, verapamil, nifedipine, nisoldipine)
Zaviralcikalcijevihkanalčkov, ki se presnovijo s CYP3A4 (npr. diltiazem, verapamil, nifedipin,
Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.
Azolskiantimikotiki,vključno s posakonazolom, najbodo zato rezerviraniza bolnike, ki prejemajo alkaloid vinke, vključnoz vinkristinom, in ki nimajo alternativnih možnosti protiglivnega zdravljenja.
Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
Dokazano je,daposakonazol invitro deluje proti naslednjim mikroorganizmom:vrstiAspergillus(Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), vrstiCandida (Candidaalbicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata,
Reporting of suspected adverse reactions
Poročanjeo domnevnih neželenih učinkih
FLU = fluconazole; ITZ = itraconazole; POS = posaconazole.
FLU = flukonazol; ITZ = itrakonazol; POS = posakonazol a:
This medicine works by killing or stopping the growth of some types of fungi that can cause infections.
Tozdravilo deluje tako, da uniči nekatere vrste gliv, ki lahko povzročajo okužbe, ali ustavi njihovorast.
Children Posaconazole AHCL should not be used in children (17 years of age and younger).
Otroci ZdravilaPosakonazol AHCL senesmeuporabljatipriotrocih(starih17letali manj).
Based on pharmacokinetic data in 10 of these paediatric patients, the pharmacokinetic profile appears to be similar to patients ≥ 18 years of age.
Na podlagifarmakokinetičnihpodatkovpri10 od teh pediatričnih bolnikov jefarmakokinetičniprofil videtipodoben kot pri bolnikih, starih ≥18 let.
What Posaconazole AHCL is and what it is used for What you need to know before you take Posaconazole AHCL How to take Posaconazole AHCL Possible side effects
Kaj je zdravilo Posakonazol AHCL in za kaj ga uporabljamo Kajmorate vedeti, preden boste vzeli zdravilo Posakonazol AHCL Kako jemati zdravilo Posakonazol AHCL Možni neželeni učinki
Ask your pharmacist how to throw away medicines you no longer use.
načinuodstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Midazolam and other benzodiazepines metabolised by CYP3A4
Midazolam in drugibenzodiazepini, ki se presnovijo s CYP3A4
Sixteen patients 8-17 years of age were treated with posaconazole oral suspension 800 mg/day in a study for invasive fungal infections (Study 0041).
Šestnajst bolnikov, starih od 8 do 17 let,so v študiji invazivnih glivnih okužb zdravili s peroralnosuspenzijo posakonazola v odmerku 800 mg/dan (študija0041).
If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended.
V primeru sočasne uporabe jepriporočljivo skrbno spremljanje celotne krvne slikeinneželenihučinkov,povezanih s povečanokoncentracijo rifabutina (npr. uveitisa).
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Če imate dodatna vprašanja o uporabi zdravila, se posvetujtezzdravnikom, farmacevtom alimedicinsko sestro.
The expiry date refers to the last day of that month.
Rokuporabnosti zdravila se izteče na zadnji dan navedenegameseca.
Refractory invasive fungal infections (IFI)/patients with IFI intolerant to 1st line therapy
Rezistentne invazivne glivneokužbe/bolniki z rezistentnoglivno okužbo, ki ne prenašajozdravljenja 1. izbora
The safety of posaconazole tablet has been assessed in 336 patients and healthy volunteers enrolled in clinical trials.
Varnost tablet posakonazola so ocenili pri 336 bolnikih in zdravih prostovoljcih, vključenih v klinična preskušanja.Varnostniprofil tablet je podoben varnostnemu profilu peroralnesuspenzije.
As observed with other azole antifungal agents, effects related to inhibition of steroid hormone synthesis were seen in repeated-dose toxicity studies with posaconazole.
Kot so opažali tudi pri drugih azolskih antimikotikih, so v študijah toksičnosti ponavljajočih se odmerkov posakonazola opaziliučinke, povezane zzaviranjemsinteze steroidnih hormonov.
Based on the available data in 16 of these paediatric patients, the safety profile appears to be similar to patients ≥ 18 years of age.
Napodlagirazpoložljivihpodatkovza 16 od teh pediatričnih bolnikov jevarnostniprofil zdravila videti podoben kot pri bolnikih, starih ≥18 let.
Treatment of azole-susceptible Oropharyngeal Candidiasis (OPC) A randomised, evaluator-blind, controlled study was completed in HIV-infected patients with azolesusceptible oropharyngeal candidiasis (most patients studied had C. albicans isolated at baseline).
Randomizirana, s "slepim ocenjevalcem"kontrolirana študija je bila opravljena pri bolnikih, okuženihz virusomHIV, ki so imeli na azole občutljivo orofaringealno kandidozo (pri večini bolnikov v tejštudijisonazačetkuštudijeizolirali C. albicans).
Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1): - Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; - Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; - Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole; - Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.
Zdravilo Posakonazol AHCL peroralna suspenzija je indicirano za zdravljenje naslednjih glivnih okužb pri odraslih (glejte poglavje 5.1): - invazivne aspergiloze pri bolnikih z okužbo, odporno na amfotericin B ali itrakonazol, ter pri bolnikih, ki ne prenašajo teh zdravil, - fuzarioze pri bolnikih z okužbo, odporno na amfotericin B, ter pri bolnikih, ki ne prenašajo amfotericina B, - kromoblastomikoze in micetoma pri bolnikih z okužbo, odporno na itrakonazol, ter pri bolnikih,
INFORMATION IN BRAILLE Posaconazole AHCL
PODATKI V BRAILLOVI PISAVI Posakonazol AHCL
Gender The pharmacokinetics of posaconazole are comparable in men and women.
Spol Farmakokinetika posakonazola jepri moškihin ženskah primerljiva.
The majority (377/600, [63 %]) of patients included had Acute Grade 2 or 3 or chronic extensive (195/600, [32.5%]) GVHD at study start.
Ključni sekundarni opazovani dogodekjebila pojavnostdokazanihoziromaverjetnih invazivnihglivnihokužb med obdobjemzdravljenja (odprvegaodmerkadozadnjegaodmerkaproučevanegazdravila + 7 dni).Večina(377/600,[63%]) vštudijo vključenih bolnikov je imela na začetku študije akutno GVHD stadija 2 ali 3 ali kronično obsežno GVHD (195/600, [32,5 %]).
Co-administration of posaconazole with H2 receptor antagonists should be avoided if possible.
Sočasni uporabi posakonazola in antagonistov receptorjevH2sejetreba izogibati, če je le mogoče.
acute renal failure, renal failure, blood creatinine increased
akutnaodpovedledvic,odpovedledvic,zvišanjeravnikreatinina v krvi
§, electrocardiogram abnormal palpitations, bradycardia, supraventricular extrasystoles, tachycardia
sindromdolgega QT§,nenormalen elektrokardiogram§,palpitacije,bradikardija,supraventrikularne ekstrasistole, tahikardija
Do not take Posaconazole AHCL if any of the above apply to you.
Ne vzemite zdravila Posakonazol AHCL, če kaj od naštetega velja za vas.
Some patients have also reported feeling confused after taking Posaconazole AHCL, the frequency of this is not known.
Nekateri bolniki so po jemanju zdravila Posakonazol AHCL poročali tudi o občutkuzmedenosti;pogostnosttegani znana.
You may feel dizzy, sleepy, or have blurred vision while taking Posaconazole AHCL, which may affect your ability to drive or use tools or machines.
Vpliv na sposobnost upravljanja vozil in strojev Med jemanjem zdravila Posakonazol AHCL ste lahko omotični, zaspani ali imate zamegljen vid, kar lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
Certain medicines may increase the risk of side effects of Posaconazole AHCL by increasing the amount of Posaconazole AHCL in the blood.
Določena zdravila lahko povečajo tveganje zapojavneželenih učinkovzdravila Posakonazol AHCL, kerpovečajokoličinozdravilaPosakonazol AHCL vkrvi.
The other ingredients in the suspension are macrogolglycerol hydroxystearate, sodium citrate dihydrate, citric acid monohydrate, simeticone emulsion (containing polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) and sulfuric acid (E513)), xanthan gum (E415), sodium benzoate (E211), liquid glucose, glycerol (E422), titanium dioxide (E171), strawberry flavour (containing propylene glycol) and purified water.
Pomožne snovi v suspenziji so makrogolglicerol hidroksistearat, natrijev citrat dihidrat, citronska kislina monohidrat, emulzija simetikona (vsebuje polidimetilsiloksan, polietilenglikol sorbitan tristearat, metilcelulozo, silikagel, polietilenglikol stearat, sorbinsko kislino (E200), benzojsko kislino (E210) in žveplovo kislino (E513)), ksantanski gumi (E415), natrijev benzoat (E211), tekoča glukoza,
Posaconazole increased Cmax and AUC of tacrolimus (0.05 mg/kg body weight single dose) by 121 % and 358 %, respectively.
Takrolimus Posakonazolje povečal Cmaxtakrolimusa(enkratni odmerek0,05 mg/kg telesne mase)za121 %innjegovo
- infections in the mouth or throat area (known as “thrush”) caused by fungi called Candida, which were not previously treated.
- okužb v predeluustaližrela(znanepodimenom“sor”),kijihpovzročagliva Candida in katerepredhodno še niso bile zdravljene.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Omogočanamrečstalnospremljanjerazmerjamedkoristmiintveganjizdravila.Odzdravstvenihdelavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila nanacionalnicenter za poročanje, ki je naveden v Prilogi V.
Patients with a low body weight (< 60 kg) are more likely to experience higher plasma concentrations of posaconazole and should be closely monitored for adverse events.
Zato je bolnike, ki tehtajo več kot 120 kg, priporočljivo skrbno spremljati glede prebijajočih glivnih okužb.Bolniki z majhno telesno maso (< 60 kg) imajo večjo verjetnost za povečane koncentracije posakonazola v plazmi in jih je trebaskrbno spremljati glede neželenih učinkov.
Adrenal suppressive effects were observed in toxicity studies in rats and dogs at exposures equal to or greater than those obtained at therapeutic doses in humans.
Vštudijahtoksičnosti na podganah in psih so opažali supresivne učinke na nadledvično žlezo pri izpostavljenostih, ki so bile enake ali večje od izpostavljenosti, dosežene s terapevtskimiodmerki pričloveku.
Study 1899 was a randomised, evaluator-blinded study of posaconazole oral suspension (200 mg three times a day) versus fluconazole suspension (400 mg once daily) or itraconazole oral solution (200 mg twice a day) in neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukaemia or myelodysplastic syndromes.
Študija1899 je bila randomizirana, za ocenjevalce slepa študija,kijeprimerjala uporabo peroralne suspenzije posakonazola (200 mg trikrat na dan) in suspenzije flukonazola (400 mgenkratnadan)aliperoralne raztopine itrakonazola (200 mg dvakrat na dan) pri bolnikih z nevtropenijo, ki so prejemalicitotoksično kemoterapijo zaradi akutne mieloične levkemije ali mielodisplastičnih sindromov.
Do not take Posaconazole AHCL - if you are allergic to posaconazole or any of the other ingredients of this medicine (listed in section 6).
- če ste alergični na posakonazol ali katerokoli sestavino tega zdravila (navedeno v poglavju6).
pancreatitis, abdominal distension, enteritis, epigastric discomfort, eructation, gastrooesophageal reflux disease, oedema mouth
pankreatitis, abdominalna distenzija, enteritis, nelagodje v epigastriju, spahovanje, gastroezofagealna refluksna bolezen,edem v ustih
Cases of elevated ciclosporin levels resulting in serious adverse reactions, including nephrotoxicity and one fatal case of leukoencephalopathy, were reported in clinical efficacy studies.
V študijah klinične učinkovitosti so poročali o primerih povečane koncentracije ciklosporina, ki je povzročila resne neželeneučinke, vključno znefrotoksičnostjo in enim smrtnim primerom levkoencefalopatije.
Caution should be used when prescribing Posaconazole AHCL to patients with hypersensitivity to other azoles.
Pri predpisovanju zdravila Posakonazol AHCL bolnikom, preobčutljivim na druge azole, je potrebna previdnost.
9 of 11 patients were successfully treated with posaconazole oral suspension 800 mg/day in divided doses for a median of 268 days and up to 377 days.
9 od 11 bolnikov so uspešno zdravilis peroralno suspenzijo posakonazola 800 mg/dan v deljenihodmerkih.Srednjavrednosttrajanjazdravljenja jebila268 dni,zdravljenjepaje lahko trajalodo377 dni.
On the first day of treatment take 200 mg (one 5 mL spoonful) once.
Prvi dan zdravljenja zaužijte enkrat 200 mg(eno polno 5 mlžličko).
There were fewer breakthrough Aspergillus infections in patients receiving posaconazole prophylaxis when compared to control patients.
Med bolniki, ki so prejemaliprofilakso sposakonazolom, jebilo prebijajočih okužb z Aspergillusommanj kot med primerjalnimi bolniki.
vomiting, abdominal pain, diarrhoea, dyspepsia, dry mouth,
bruhanje, bolečine v trebuhu, diareja, dispepsija, suha usta,
NAME OF THE MEDICINAL PRODUCT Posaconazole AHCL 40 mg/mL oral suspension
IME ZDRAVILA Posakonazol AHCL 40 mg/ml peroralna suspenzija
The duration of therapy is based on recovery from neutropenia or immunosuppression.
Trajanjezdravljenja je odvisno od okrevanja po nevtropeniji aliimunosupresiji.
Treatment with these HMG-CoA reductase inhibitors should be discontinued during treatment with posaconazole as increased levels have been associated with rhabdomyolysis (see section 4.3).
Med zdravljenjem s posakonazolomjetrebazdravljenje z zaviralci reduktazeHMG-CoAprekiniti, ker so bile povečane koncentracije povezane z rabdomiolizo (glejte poglavje 4.3).
What you need to know before you take Posaconazole AHCL
Kaj morate vedeti, preden boste vzeli zdravilo Posakonazol AHCL
Five of these patients had chromoblastomycosis due to Fonsecaea pedrosoi and 4 had mycetoma, mostly due to Madurella species.
Petod teh bolnikov je imelo kromoblastomikozo zaradi okužbe sFonsecaea pedrosoi,
Always take this medicine exactly as your doctor or pharmacist has told you.
Prijemanju tega zdravila natančno upoštevajte navodila zdravnika ali farmacevta.
Study 316 was a randomised, double-blind trial of posaconazole oral suspension (200 mg three times a day) versus fluconazole capsules (400 mg once daily) in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD).
Študija316 je bila randomizirano, dvojno slepo preskušanje s peroralno suspenzijo posakonazola(200 mgtrikrat na dan) v primerjavi s kapsulami flukonazola (400 mgenkratnadan)pri bolnikih poalogenskitransplantacijihematopoetskih matičnih celic zreakcijo presadka proti gostitelju
Posaconazole AHCL 40 mg/mL oral suspension posaconazole
Posakonazol AHCL 40 mg/ml peroralna suspenzija posakonazol
pyrexia (fever), asthenia, fatigue
pireksija, astenija, utrujenost
As a result, sirolimus trough concentrations that fall within the usual therapeutic range may result in sub-therapeutic levels.
Zaradi tega lahko najnižja koncentracija sirolimusa, ki ješe vobičajnemterapevtskem razponu, dejansko pomeni koncentracijo,nižjo od terapevtske.
Whenever possible you should take posaconazole during or immediately after food or a nutritional drink.
Čejele mogoče,posakonazol vzemite med ali takoj po jedi ali zaužitju prehranskega dopolnila vobliki napitka.
The microbiological data suggest that posaconazole is active against Rhizomucor, Mucor, and Rhizopus; however the clinical data are currently too limited to assess the efficacy of posaconazole against these causative agents.
Rhizopus;vendar jekliničnih podatkovtrenutno premalo, da bi lahko ocenili učinkovitost posakonazola proti tem povzročiteljem okužb.
If you forget to take Posaconazole AHCL
Če ste pozabili vzeti zdravilo Posakonazol AHCL
Posaconazole AHCL contains glucose
Zdravilo Posakonazol AHCL vsebuje glukozo
Treatment of refractory Fungal Infections (Invasive aspergillosis, Fusariosis,
Zdravljenje rezistentnih glivnih okužb (invazivna aspergiloza,fusarioza,kromoblas tomikoza/micetom, kokcidioidomikoza)
Posaconazole was shown to be non-inferior to fluconazole for clinical success rates at Day 14 as well as 4 weeks after the end of treatment.
Za posakonazol so pokazali, da po klinični uspešnosti, ugotovljeni na 14. dan in 4tedne po koncu zdravljenja, ni nič slabši od flukonazola.
However, as posaconazole is not significantly renally eliminated, an effect of severe renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended.
Ker pa seposakonazol skozi ledvice neizloča v pomembnimeri, ni pričakovati, da bi huda okvara ledvicvplivalana farmakokinetiko posakonazola;prilagajanje odmerka tako ni potrebno.Posakonazolseneodstranjuje s hemodializo.
Several of the interaction studies were conducted in healthy volunteers in whom a higher exposure to posaconazole occurs compared to patients administered the same dose.
Pri zdravih prostovoljcih je bilo opravljenihvečštudij medsebojnega delovanjaposakonazola z drugimi zdravili, pri katerih jebila izpostavljenost posakonazolu večja kot pri bolnikih, ki so prejemali enakodmerek.
The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown.
23 %.Vpliv posakonazola nakoncentracijo fosamprenavirja v primeru uporabe fosamprenavirja zritonavirjem ni znan.
In a study (Study 03579) of 136 neutropenic paediatric patients 11 months - 17 years treated with posaconazole oral suspension at doses up to 18 mg/kg/day divided TID, approximately 50% met the pre-specified target (Day 7 Cav between 500 ng/mL-2,500 ng/mL) (see section 5.2).
Vštudiji(študija03579) pri 136 nevtropeničnih pediatričnih bolnikih, starih od 11 mesecevdo 17 let, zdravljenih s peroralno suspenzijo posakonazola v odmerkihdo 18 mg/kg/dan, razdeljenih na tri odmerke dnevno, je približno 50 % bolnikov doseglo vnaprejdoločen cilj (povprečna koncentracija v stanju dinamičnega ravnovesja (Cav) 7. dan med 500